RxDoctor Payments Data

Mary Norris, PA

Physician Assistant · Memphis, TNNPI 1306310230

Payments from drug & device makers

$2,830in general payments, 2019–2025

Across 195 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$322
  • SK Life Science, Inc.$292
  • Pfizer$195
  • Biogen$181
  • Acadia Pharmaceuticals Inc$138
  • plus $552 from 12 others

What the payments were for

  • Food & beverage$2,822100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,830 in reported general payments places this provider in the 80th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$173,229
Medicare patients
309
Services billed
9,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate12$59,185
AptiomEslicarbazepine Acetate20$30,431
Emgality PenGalcanezumab-Gnlm16$10,713
Aimovig AutoinjectorErenumab-Aooe12$9,952
Gabapentin256$7,302
Carbidopa-LevodopaCarbidopa/Levodopa235$6,697
Entacapone19$2,981
Memantine Hcl109$2,794
Tizanidine Hcl217$2,339
Pregabalin104$2,187
RivastigmineRivastigmine Tartrate24$1,544
Ropinirole Hcl43$1,461
Donepezil Hcl116$1,289
Pyridostigmine Bromide14$1,262
Propranolol Hcl ErPropranolol Hcl31$1,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$138$59,18512 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$17$1,26214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →